The membrane-linked docking protein SNT-2/FRS2b/ FRS3 becomes tyrosine phosphorylated in response to fibroblast growth factors (FGFs) and neurotrophins and serves as a platform for recruitment of multiple signaling proteins, including Grb2 and Shp2, to FGF receptors or neurotrophin receptors. We previously reported that SNT-2 is not tyrosine phosphorylated significantly in response to epidermal growth factor (EGF) but that it inhibits ERK activation via EGF stimulation by forming a complex with ERK2. In the present report, we show that expression of SNT-2 suppressed EGF-induced cell transformation and proliferation, and expression level of SNT-2 is downregulated in cancer. The activities of the major signaling molecules in EGF receptor (EGFR) signal transduction pathways, including autophosphorylation of EGFR, were attenuated in cells expressing SNT-2 but not in cells expressing SNT-2 mutants lacking the ERK2-binding domain. Furthermore, SNT-2 constitutively bound to EGFR through the phosphotyrosine binding (PTB) domain both with and without EGF stimulation. Treatment of cells with MEK inhibitor U0126 partially restored the phosphorylation levels of MEK and EGFR in cells expressing SNT-2. On the basis of these findings, we propose a novel mechanism of negative control of EGFR tyrosine kinase activity with SNT-2 by recruiting ERK2, which is the site of negative-feedback loop from ERK, ultimately leading to inhibition of EGF-induced cell transformation and proliferation.
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Introduction
Signaling pathways through receptor tyrosine kinases control a variety of cellular processes, such as cell proliferation and oncogenesis, both under physiological and pathological conditions. Membrane-linked docking/ adaptor proteins SNT-1 and SNT-2 become tyrosine phosphorylated in response to fibroblast growth factors (FGFs) or neurotrophins and play major roles in mediating intracellular signaling (Rabin et al., 1993; Kouhara et al., 1997; Ong et al., 2000; Schlessinger, 2000; Hadari et al., 2001; Gotoh et al., 2004b) . SNT-1 and SNT-2 are also known as FRS2a and FRS2b or FRS3, respectively. Both proteins contain myristyl anchors and phosphotyrosine binding (PTB) domains in their N termini and multiple tyrosine phosphorylation sites in their C termini that serve as docking sites for adaptor protein Grb2 and protein tyrosine phosphatase Shp2 (Kouhara et al., 1997; Hadari et al., 1998; Xu et al., 1998; Gotoh et al., 2004a, b; Harada et al., 2005) . It has been reported that SNT-1/FRS2a mediates multiple FGF-induced cellular responses, including stimulation of the Ras/ERK cascade and activation of phosphatidylinositol (PI)-3 kinase Ong et al., 2001) . Snt-1/Frs2a-null mouse embryos show early embryonic lethality due to defects in multiple FGF responses during development, indicating that SNT-1/ FRS2a is essential for FGF signaling in vivo (Gotoh et al., 2005) . Ectopic expression of SNT-2/FRS2b in Snt-1/Frs2a À/À mouse embryonic fibroblasts (MEFs) compensates for the loss of SNT-1/FRS2a in activation of ERK in response to FGF, indicating that SNT-1/ FRS2a and SNT-2/FRS2b have redundant roles in FGF signaling (Gotoh et al., 2004b) .
In epidermal growth factor receptor (EGFR) signaling, direct binding of Grb2 to the receptor or formation of the Shc-Grb2 complex plays a major role in activation of the Ras/ERK cascade (Rozakis-Adcock et al., 1992; Buday and Downward, 1993; Li et al., 1993; Gotoh et al., 1994 Gotoh et al., , 1995 Jorissen et al., 2003) . Although it has been reported that SNT-1/FRS2a becomes tyrosine phosphorylated and activates ERK at moderate levels upon stimulation with epidermal growth factor (EGF) (Wu et al., 2003) , SNT-2/FRS2b does not show EGF-induced tyrosine phosphorylation at significant levels or activation of ERK (Huang et al., 2004; Gotoh et al., 2004b) . We previously showed that SNT-2/FRS2b binds to ERK2 and inhibits activation of ERK in response to EGF (Huang et al., 2004) .
EGFR has been implicated in oncogenesis in both mammalian and avian species. In humans, amplification of EGFR gene or overexpression of EGFR has been observed in many tumors (Yarden and Sliwkowski, 2001 ). EGFR induces cell transformation and proliferation in a ligand-dependent manner (Riedel et al., 1988; Gotoh et al., 1992 Gotoh et al., , 1994 . As it is thought that activation of the Ras/ERK cascade plays an important role in cell proliferation and oncogenesis stimulated by EGFR tyrosine kinases, we examined the effects of SNT-2/ FRS2b on these biological processes.
In the present study, we found that SNT-2/FRS2b inhibits EGF-induced cell transformation and proliferation, and expression level of SNT-2/FRS2b is downregulated in cancer. We then examined the molecular mechanisms that underlie these inhibitory effects and found that SNT-2/FRS2b contitutively binds to EGF receptor regardless of EGF stimulation and that it inhibits activation of many of the signaling proteins in EGF signaling pathways, including autophosphorylation of EGFR. These inhibitory effects were not observed when the ERK2-binding domain was deleted from SNT-2/FRS2b. Finally, activation of ERK is required for full inhibition. On the basis of these results, we propose that recruitment of ERK2 to SNT-2/ FRS2b-EGFR complex negatively controls the activity of EGFR tyrosine kinase and thus reduces EGF signaling. Our findings suggest that manipulation of SNT-2/FRS2b may be a useful strategy for treatment of cancers in which cell growth is stimulated by EGFRinduced signaling pathways.
Results

SNT-2 impairs the transforming activity of EGFR induced by EGF
To investigate the biological activity of SNT-2, we performed transformation assays using a subclonal NIH3T3 cell line, which does not express functional endogenous EGFR (Gotoh et al., 1992 (Gotoh et al., , 1994 . We took advantage of the fact that exogenously transfected EGFR transforms the NIH3T3 cells in the presence of EGF (Riedel et al., 1988; Gotoh et al., 1992 Gotoh et al., , 1994 . EGFR expression vector carrying a hygromycin-resistance cassette with or without SNT-2 expression vector containing a neomycin-resistance cassette were transfected into NIH3T3 cells. Cells were then exposed to EGF or no growth factor, and G418-hygromycin resistant-colonies with transformed morphology and normal morphology were counted separately (Figure 1a and b). In the absence of EGF, whereas a few transformed colonies were observed when vector-expressing EGFR alone was transfected, no transformed colonies were obtained in the co-transfection of vectors for EGFR and SNT-2 (Figure 1b) . On EGF stimulation, transfection of EGFR expression vector alone produced a high percentage of transformed colonies (87%). Co-transfection with increasing amounts of SNT-2 expression vector reduced the percentage of transformed colonies (53-24%) (Figure 1b ) as well as number and sizes of hygromycin plus G418 resistant colonies in a dose-dependent manner. We then examined expression of SNT-2 and EGFR in several colonies. The ratios of SNT-2 level to EGFR level were much higher in untransformed colonies than those in transformed colonies, being consistent with that SNT-2 suppressed the transformation (Figure 1c ). These results suggest that SNT-2 interferes with the EGF-induced Expression levels of SNT-2 are downregulated in tumor cell lines We previously reported that Snt-2/Frs2b mRNA is expressed in normal tissues including brain and several restricted tissues including lung epithelia (Gotoh et al., 2004b) . To investigate the physiological and pathological relevance of the effect of SNT-2, we compared expression levels of SNT-2 in normal brain tissue vs two cell lines derived from brain tumors, and also those in a cell line derived from normal lung tissue vs seven cell lines derived from lung cancers. The results suggest that SNT-2 is expressed at lower levels in all the cell lines derived from brain tumor or lung cancer compared with corresponding normal tissue or a cell line derived from normal tissue (Figure 2 ). Figure 3a) . However, no such extensive downregulation was observed in cells expressing an SNT-2 mutant, D186-252, that lacks the ERK2-binding domain ( Figure 3a ) (Huang et al., 2004) .
Activated MEK specifically activates ERK by phosphorylation of the Thr-X-Tyr motif (Payne et al., 1991; Canagarajah et al., 1997) . To study whether SNT-2 directly or indirectly suppresses the phosphorylation of Figure 2 Expression of endogenous SNT-2 by immunoblotting. NB, normal mouse brain; 1, T98G; 2, SH-SY5Y; NL, WI38 VA13, derived from normal embryonic lung epithelia; 3, PC10; 4, LK2; 5, H520; 6, H157; 7, PC14; 8, PC3; 9, H322. Total cell lysates were immunoblotted (IB) with indicated antibodies. SNT-2/FRS2b negatively regulates EGFR signaling L Huang et al ERK2 by MEK, we transiently transfected a constitutively active (CA) mutant of MEK1, CAMEK1, into stable SNT-2 transfectants. Phosphorylation of ERK2 by CAMEK1 was not suppressed by SNT-2 or D186-252 (Figure 3b ), suggesting that even in the presence of excess SNT-2, activated pMEK1 can phosphorylate ERK2. Thus, SNT-2 indirectly inhibits activation of ERK. These results are consistent with the notions that SNT-2 downregulates ERK2 phosphorylation in response to EGF at a step upstream of or parallel to MEK and further that binding of ERK2 to SNT-2 is necessary for the downregulation.
SNT-2-ERK2 interaction downregulates signaling via the EGFR/Ras/ERK pathway To determine at which step SNT-2 downregulates signaling from EGFR to MEK post-EGF stimulation, we first carried out in vitro binding assays to examine Ras activation. SNT-2 stable transfectants were treated with EGF, and levels of activated Ras were evaluated by binding to the Ras-binding domain (RBD) of Raf. Ras showed lower levels of binding to RBD in SNT-2-expressing cells than in empty vector-transfected cells. However, the binding affinity was recovered partially in D186-252-expressing cells (Figure 3c , upper panels), suggesting that Ras activation or signaling further upstream is affected by SNT-2.
Shc and PLCg bind directly to autophosphorylated EGFR, and it is thought that these proteins are phosphorylated by activated EGFR (Yarden and Sliwkowski, 2001) . We examined tyrosine phosphorylation of Shc, PLCg and EGFR. Phosphorylation levels of these proteins were lower in SNT-2-expressing cells than in D186-252-expressing cells or in empty vector-transfected cells ( Figure 3c , lower panels). To confirm the results, HEK 293 cells were co-transfected with EGFR and SNT-2 expression plasmids, and we found that the tyrosine phosphorylation of EGFR was reduced ( Figure 3d ). Taken together, these results suggest that the SNT-2-ERK2 interaction downregulates EGFR/Ras/ERK signaling at autophorphorylation step of EGFR.
SNT-2 binds to EGFR constitutively Our finding that SNT-2 downregulated phosphorylation of EGFR prompted us to ask whether SNT-2 binds to EGFR. The lysates of SNT-2 stable transfectants were subjected to co-immunoprecipitation (IP) with anti-EGFR antibodies followed by immunoblotting with anti-FLAG antibody. SNT-2 was found to be co-IP with anti-EGFR antibodies no matter whether treated with EGF or not (Figure 4a , upper panels). In order to investigate the interaction of endogenous SNT-2, EGFR and ERK2, the lysate of mouse brain was subjected to co-IP with anti-SNT-2-C antibodies followed by immunoblotting with antibodies for EGFR, SNT-2 and ERK2. The results suggest that SNT-2 interacts with endogenous EGFR and ERK2 in the mouse brain lysate (Figure 4a , lower panels).
To examine which region of SNT-2 mediates the interaction with EGFR, we transiently transfected vectors expressing full-length or mutant forms corresponding to amino acids 1-185 (PTB domain) and 186-328 of SNT-2 (Figure 5a ) into HEK 293 cells, and the cell lysates were subjected to co-IP with anti-EGFR antibodies. Full-length and mutant 1-185 were co-IP with anti-EGFR antibodies, but mutant 186-328 was not (Figure 4b ). These results suggest that the EGFRbinding domain is located in the PTB domain, which also mediates the interaction with FGF receptor and neurotrophin receptors (Dhalluin et al., 2000; Ong et al., 2000) . In many cases, the PTB domain binds to phosphotyrosine residues, but SNT-2 bound to EGFR in serum-starved cells. Therefore, we examined whether SNT-2 binds to phosphotyrosine residues of EGFR. We co-transfected vector expressing wild-type EGFR or the F5 mutant of EGFR, which lacks all of the major Figure 4 Binding of SNT-2 to EGFR. (a) upper panels; Saos-2 cells stably transfected with SNT-2-FLAG ( þ ) or empty vector (À) were treated with EGF (50 ng/ml) for 10 min after 24 h of serum starvation. Cell lysates were subjected to co-immunoprecipitation (IP) with anti-EGFR antibodies. (a) Lower panels; mouse brain lysate was subjected to co-IP with anti-SNT-2-C antibodies. The IP and lysate were immunoblotted with the indicated antibodies. The immunoblotting of SNT-2 in lower panels was performed with biotinylated anti-SNT-2-C antibodies. (b) HEK 293 cells transiently transfected with full length SNT-2-FLAG, 1-185-FLAG, 186-328-FLAG, or empty vector (À) were treated as described in (a), upper panels. Cell lysates were subjected to co-IP, and the IP and TCL were immunoblotted with the indicated antibodies. (c) HEK 293 cells transiently transfected with EGFR wild-type or F5 mutant expression vector together with or without SNT-2-FLAG expression vector were treated as described in (a), upper panels. Cell lysates were subjected to co-IP, and the IP and TCL were immunoblotted with the indicated antibodies.
SNT-2/FRS2b negatively regulates EGFR signaling L Huang et al authophosphorylation sites of EGFR (Okutani et al., 1994) , with vector expressing SNT-2 into HEK 293 cells, and the cell lysates were subjected to co-IP with anti-EGFR antibodies. SNT-2 interacted with mutant F5 as well as wild-type EGFR (Figure 4c ). Thus, SNT-2 binds to EGFR at a site(s) other than the major sites of tyrosine autophosphorylation.
SNT-2 downregulates phosphorylation of other MAPKs
To narrow the region of SNT-2 that interacts with ERK2, we generated additional FLAG-tagged SNT-2 mutants and expressed them in HEK 293 cells (Figure 5a ). Cell lysates were subjected to pull-down assays. The results that glutathione S-transferase (GST)-ERK2 bound to D1-252 but neither to D1-236 nor to D237-252 suggest that the region of amino acids 237-252 of SNT-2 is required for binding to ERK2 (Figure 5a ). To further explore the role of SNT-2 in EGF signaling, we investigated the phosphorylation of JNK and p38 upon EGF stimulation in the stable transfectants of Saos-2 cells expressing internal deletion mutant lacking the ERK2-binding domain, D237-252, and fulllength SNT-2. In SNT-2-expressing cells, the levels of phosphorylation of JNK and p38 were lower than those of empty vector-transfected cells. However, in D237-252-expressing cells, the phosphorylation levels of JNK and p38 were similar to those of vector-transfected cells (Figure 5b ). We made three stable cell lines for each SNT-2 construct and obtained essentially same results. As SNT-2 inhibits EGFR-mediated activation of so many signaling proteins, it is reasonable to speculate that EGFR is a target of the SNT-2-ERK2 complex for downregulation of EGFR signaling.
ERK activation downregulates EGFR signaling via SNT-2-ERK2 interaction
As the ERK2-binding domain of SNT-2 is essential for the inhibitory effect of SNT-2 on EGF signaling, we next examined whether activation of ERK is required for these effects. We treated the SNT-2-, D237-252-or empty vector-transfectants with MEK inhibitor U0126 before EGF stimulation to inhibit activation of ERK. We found that the levels of phosphorylation of EGFR and MEK in U0126-treated cells expressing SNT-2 in response to EGF were higher than that of U0126-untreated cells (Figure 6 ). However, in empty vectortransfected cells and D237-252-expressing cells, the phosphorylation levels of EGFR and MEK were not changed in either U0126-treated or untreated condition. Thus, activation of ERK appears to play an important role in downregulating EGFR signaling through the SNT-2-ERK2 complex.
SNT-2-ERK2 complex inhibits cell proliferation on EGF stimulation
To examine the effects of SNT-2 on cell proliferation, we used a retrovirus system to transiently transduce fulllength SNT-2 and D237-252 in NIH3T3 cells expressing EGFR. This system allowed transient expression of SNT-2 at approximately 100% efficiency as detected by immunostaining of transduced cells with anti-FLAG antibody (data not shown). 
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We examined expression levels of endogenous Snt-2 and Snt-1 transcripts in NIH3T3 cells and mouse brain by Northern blotting. Snt-1 transcript levels were high in both cell types, whereas Snt-2 transcript level in NIH3T3 cells was very low in comparison to that in brain (Figure 7a, upper panels) . This is consistent with our previous finding that Snt-2/Frs2b is expressed at high levels in restricted areas, including nervous tissues, whereas expression of Snt-1/Frs2a is ubiquitous (Gotoh et al., 2004b) . Western-blot analysis revealed that the level of expression of SNT-2 in transiently introduced NIH3T3 cells was similar to the endogenous level in brain (Figure 7a, lower panels) .
We found that the levels of phosphorylation of MEK and ERK upon EGF stimulation were lower in SNT-2-expressing cells than those in empty vector-transduced cells. However, in D237-252-expressing cells, the levels of phosphorylation of MEK and ERK were restored (Figure 7b ).
When serum-starved, NIH3T3 cells did not grow significantly (Figure 7c ). When we stimulated cells with EGF, the empty vector-transduced cells proliferated Figure 6 Partial recovery of the inhibition of EGFR and MEK phosphorylation by SNT-2 with U0126 treatment. Saos-2 cells stably transfected with vector expressing SNT-2-FLAG, or D237-252-FLAG or empty vector (À) were serum starved for 24 h and treated with U0126 (10 mM) for 1.5 h prior to EGF treatment (50 ng/ml) for 10 min. TCL were analyzed by immunoblotting with the indicated antibodies. EGFR-expressing NIH3T3 cells were transduced with retrovirus carrying SNT-2-FLAG, or D237-252-FLAG or empty vector (À) and then treated with EGF (50 ng/ml) for 10 min after 24 h of serum starvation. TCL were analysed by immunoblotting with the indicated antibodies. Levels of phosphorylation on MEK1 and ERK1/2 were quantified with NIH image. (c) Cell growth assays of EGFR-expressing NIH3T3 cells transduced with retrovirus carrying SNT-2-FLAG, or D237-252-FLAG, or empty vector. Upper panels; Triangle, empty vector; square, full-length SNT-2; circle, D237-252 SNT-2. Lower panels; different amounts of retrovirus carrying SNT-2 were used to change the expression level of SNT-2. Triangle, empty vector; square, SNT-2; circle, 1/10 SNT-2. Results were indicated by the mean7s.d. of the cell numbers from two independent experiments. The expression levels of SNT-2 were examined by immunoblotting. (d) Soft agar colony formation assays. Results were indicated by the mean þ s.d. of the cell numbers from three independent experiments. White columns, no stimulation; black columns, EGF stimulation. *Po0.05, **Po0.01.
efficiently in response to EGF, consistent with our previous results (Gotoh et al., 1997) (Figure 7c ). The D237-252-expressing cells proliferated faster than empty vector-transduced cells in the presence of EGF (Figure 7c , upper panels). However, SNT-2-expressing cells proliferated at a rate slower than any of the others in the presence of EGF. To confirm the inhibitory effects of SNT-2, cells were transduced with retrovirus carrying SNT-2 at 1/10 concentration (1/10 SNT-2) of the one without dilution (SNT-2). As shown in lower panels of Figure 7c , cells transduced with 1/10 SNT-2 grew faster than cells transduced with the one without dilution. However, cells transduced with 1/10 SNT-2 grew slower than empty vector-transduced cells. These results indicate that full-length SNT-2 but not D237-252 inhibits growth of NIH3T3 cells in response to EGF, and this inhibition is dose-dependent. We next examined whether expression of full length SNT-2 or mutant D237-252 inhibits anchorage independent cell growth using soft agar colony formation assay. Without EGF treatment, NIH3T3 cells transduced with empty vector or SNT-2 did not yield any colony, whereas only D237-252-expressing cells showed recognizable colonies. When we treated cells with EGF, SNT-2-expressing cells exhibited a marked decrease in colony number (B35% reduction) compared with empty vector-transduced cells, while D237-252-expressing cells showed much more colonies than empty vector-transduced cells (B80% increase). In addition, colonies of SNT-2-expressing cells were smaller than those of empty vector-transduced cells or D237-252-expressing cells in the presence of EGF (Figure 7d ).
Discussion
Here, we report that SNT-2 binds constitutively to EGFR and that ERK2 is recruited to the SNT-2-EGFR complex at the cytoplasmic membrane, which negatively regulates autophosphorylation of EGFR and thus suppresses the downstream EGFR signaling, ultimately leading to inhibition of cell transformation and proliferation induced by EGF. Thus, we propose a novel mechanism of negative control of EGFR tyrosine kinase activity where SNT-2 plays as a platform for negativefeedback loop from EGFR to ERK. Further, this negative-feedback loop ultimately leads to inhibition of EGF-induced cell transformation and proliferation. Therefore, SNT-2 is a unique protein that negatively regulates signaling pathways through EGFR, in general, as evidenced from the results that both p38 and JNK phosphorylation were attenuated. We believe that due to these characteristics we are able to make use of SNT-2 to target cancers in which EGFR signaling pathways are hyperactivated.
How does SNT-2 inhibit activation of EGFR in details? We found that SNT-2 binds to EGFR constitutively in both the EGF-stimulated and unstimulated conditions (Figure 4 ) and that SNT-2 but not mutants lacking the ERK2-binding domain (D186-252 and D237-252) inhibit EGFR activation (Figures 3c and   6 ). Further, we found that inhibition of activation of the MEK-ERK cascade by treatment with a MEK inhibitor partially restored the inhibitory effects of SNT-2 on activation of EGFR and MEK, suggesting that activation of ERK and the binding to SNT-2 complex are needed to suppress the functions of EGFR (Figure 6 ). Consistent with these findings, it was recently reported that upon EGF stimulation of EGFR-overexpressing cells, ERK is sequestered at the cell membrane in the EGFR-containing complexes and attenuates EGF signaling (Habib et al., 2003) , which substantiates trafficking ERK to the cell membrane upon EGF stimulation. There are primarily three mechanisms to explain the downregulation of EGFR activation: physical perturbation of autophosphorylation, dephosphorylation with tyrosine phosphatases, degradation of EGFR (i.e. by enhanced c-Cbl activation), or combination of these mechanisms. The third mechanism is not likely to be case, as the level of EGFR was not changed significantly with or without SNT-2 expression (Figures 3c, d, 4 and 7b). It is possible that some unidentified protein(s) bound to ERK2 is recruited to the SNT-2-EGFR complex and blocks EGFR autophosphorylation or dephosphorylates EGFR. The unidentified protein(s) binds with greater affinity to activated ERK2 than to inactivated ERK2, or activated ERK2 stimulates the protein(s) to inhibit EGFR tyrosine kinase. One candidate protein is a tyrosine phosphatase. Further experiments are needed to identify such protein. Another possibility is that ERK2 itself inhibits autophosphorylation of EGFR when it binds to SNT-2. A conformational change in EGFR might be induced by ERK2 binding to the complex SNT-2-EGFR or/and ERK2 might directly phosphorylate EGFR or/and SNT-2, which results in the inhibition of EGFR activation. As there is no evidence that ERK2 directly phosphorylates SNT-2 (Lax et al., 2002; Gotoh et al., 2004b; Huang et al., 2004) , detailed analysis of serine/threonine phosphorylation of EGFR is needed to clarify this point.
We previously demonstrated that the PTB domain of SNT-2 constitutively binds to FGF receptor independent of ligand stimulation and receptor activation, as was the case for SNT-2 binding to EGFR, being presented here (Figure 4b ). However, nerve growth factor (NGF) receptor binding to SNT-2 is strongly dependent on receptor activation (Ong et al., 2000) . Structural analysis revealed that different sites within the PTB domain of SNT-2 are involved in binding to FGF receptor and NGF receptor (Dhalluin et al., 2000) . It will be interesting to identify the domain of EGFR that is involved in binding to the PTB domain of SNT-2 and to analyse the structure of this complex.
Although we did not detect any increase in MEK or ERK2 activation levels in D237-252-expressing cells compared with those in empty vector-transduced cells, they showed an increase in cell growth rate and colony forming efficiencies in soft agar (Figure 7b-d) . It is possible that the mutant works as a dominant negative mutant that sequesters the endogenous SNT-2 from the EGFR. This may cause enhancing effects of the mutant on cell growth and anchorage independence. Since SNT-2 has an effect on a negative feedback loop in EGF signaling, the enhancing effects of the mutant may not be very obvious on activities of MEK and ERK2 after 10-mintreatment with EGF, instead, it may take long time until the effects of the mutant activities become obvious.
We screened many cell lines to find cells that express SNT-2 endogenously at significant levels and also proliferate in response to EGF, however, we were not able to find such cells. EGF does not stimulate proliferation of Saos-2 cells in which SNT-2 was able to be expressed stably, whereas EGF stimulates proliferation of NIH3T3 cells in which SNT-2 were not able to be expressed stably. As SNT-2 inhibits cell proliferation stimulated by EGF, proliferating cells might be needed to resist the effects of SNT-2 and to be unresponsive to EGF in order to maintain significant expression level of SNT-2.
What is the physiological role of SNT-2? The protein level of transient expression of SNT-2 in NIH3T3 cells was comparable to the endogenous level in brain, indicating that the exogenous SNT-2 was expressed at endogenous level, and therefore, the observed effects occurred at the physiological level of expression (Figure 7a ). We previously reported that Snt-2/Frs2b is expressed at high levels in specific cells and tissues, including nervous tissues and lung and gastrointestinal epithelia, whereas expression of Snt-1 is ubiquitous (Gotoh et al., 2004b) . In nervous tissues, expression of Snt-2/Frs2b and Snt-1 shows a reciprocal pattern. Snt-1 is highly expressed in ventricular zone where neural stem cells proliferate but expression of Snt-2/Frs2b is observed in areas where differentiated neuron and glia cells are localized (Gotoh et al., 2004b) . It is possible that SNT-2 inhibits cell proliferation stimulated by EGF, which results in induction of differentiation in these areas. We are presently investigating this issue.
What is a pathological role of SNT-2? We found that expression levels of SNT-2 are downregulated in cell lines derived from brain tumors or lung cancers (Figure 2 ). This result raises a possibility that expression of SNT-2 is disadvantageous for growth or survival of cells derived from tumors. In addition, many of these cell lines have been reported to be dependent on activation of EGFR signaling in terms of cellular growth: T98G (Rubenstein et al., 1999) , SH-SY5Y (Ho et al., 2005) , LK2 (Hirata et al., 2005) and H157 (Lee et al., 1992) . It is thus possible that the downregulation of SNT-2 releases the SNT-2-mediated inhibition of EGFR signaling, resulting in the promotion of cellular growth. We are presently investigating this issue.
In summary, our present data indicate that SNT-2 is a novel adaptor that binds to ERK2 and negatively controls EGFR signaling in whole. Manipulation of SNT-2 could be a useful strategy for treatment of tumors in which EGFR is highly activated.
Materials and methods
Plasmids
The full length, several C-terminal truncation mutants (amino acids 1-185, 1-202, 1-219, 1-236, 1-252) and internal deletion mutants (amino acids 186-252 (D186-252) and 237-252 (D237-252)) of human SNT-2 cDNA with C-terminal FLAG-tag expression vectors carrying neomycin-resistance gene were generated as described previously (Huang et al., 2004) . The full-length SNT-2 and mutant D237-252 with FLAG-tag in the C-termini were subcloned in a vector pMXspuro for expression using retrovirus (Kitamura et al., 2003) . cDNAs for wild-type EGFR (WT-EGFR) and its mutant, termed F5, in which the tyrosine residues at positions 992, 1068, 1086, 1148 and 1173 were replaced by phenylalanine, were previously described (Okutani et al., 1994) . The GST fusion proteins of SNT-2-C (the C-terminal region of SNT-2, amino acids 333-492) and human ERK2 were constructed by subcloning the corresponding cDNAs into vector pGEX-4T-1 as described previously (Huang et al., 2004) . The sequences of all the constructed expression plasmids were verified as having the correct reading frame by sequencing. CAMEK1 (S218 and S222 were changed to glutamic acids) is a constitutive active mutant of MEK1 from Stratagene.
Cell culture and transfection Saos-2, HEK 293, human embryonic lung epithelia WI38 VA13, neuroblastoma SH-SY5Y and gliablastoma T98G cells were cultured in Dulbecco's modified Eagle's medium (DMEM) containing 10% fetal bovine serum (FBS) at 371C in 5% CO 2 . Lung cancer PC10, LK2, H520, H157, PC14, PC3 and H322 cells were cultured in RPMI containing 10% FBS at 371C in 5% CO 2 . NIH3T3 cells were cultured in DMEM containing 5% new born calf serum (NBCS) at 371C in 5% CO 2 .
For stable transfections, Saos-2 cells plated at 1 Â 10 6 / 100 mm dish were transfected with 0.5 mg of plasmid by a standard calcium precipitation method (Chen and Okayama, 1987) . After 48 h, 400 mg/ml G418 (Calbiochem), was added and cells were cultured for additional 2 weeks. For transient transfection, HEK 293 cells plated at 2 Â 10 6 /60 mm dish were transfected with 4 mg of plasmid using LipofectAMINEt 2000 (Invitrogen, Co., Carlsbad, CA, USA) following the protocol from the company.
Retrovirus-mediated gene expression
Packaging cells Plat-E were grown in DMEM containing 10% FBS. The cells plated at 5 Â 10 6 /100 mm dish were transfected with 3 mg of plasmid using FuGENE6 (Roche Diagnostics, Indianapolis, IN, USA) following the protocol from the company. After 24 h, the media were changed and the supernatant media containing retrovirus were collected and added to NIH3T3 cells expressing EGFR 48 h later. After another 24 h, puromycin (1.6 mg/ml) was added and cells were cultured for additional 3 days (Kitamura et al., 2003) .
Antibodies
Anti-EGFR, anti-ERK2 (monoclonal D-2 and polyclonal K-23), anti-H-Ras, anti-GST, horseradish peroxidase (HRP)-conjugated anti-mouse IgG and HRP-conjugated anti-rabbit IgG antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Anti-FLAG M2 monoclonal antibody was from Sigma-Aldrich (St Louis, MO, USA). AntipERK, anti-pMEK, anti-pShc, anti-pPLCg, anti-pJNK, anti-JNK, anti-pp38 MAPK and anti-p38 MAPK antibodies were from Cell Signaling Technology. Anti-Shc antibody was a product of BD Biosciences (Franklin Lakes, NJ, USA), antiphosphotyrosine antibody was from Southern Biothech (Birmingham, AL, USA) and anti-Actin antibody was from Chemicon International Serological Co., (Temecula, CA, USA).
For anti-SNT-2 antibodies, peptides corresponding to human SNT-2 amino acids 292-311 were synthesized and rabbits SNT-2/FRS2b negatively regulates EGFR signaling L Huang et al were immunized with the peptides conjugated with KLH-MBS. The purified GST-SNT-2-C was mixed with FCA (Freund's Complete Adjuvant, for the first time alone) or FIA (Freund's Incomplete Adjuvant, for the next three times) to immunize the rabbit. The two kinds of rabbits serum was subjected to affinity purification and termed as anti-SNT-2-P and anti-SNT-2-C, respectively. A part of anti-SNT-2-C was biotinylated with EZ-Link Sulfo-NHS-LC-Biotinylation Kit (Pierce Chemical Co., Rockford, IL, USA) following the protocol from the company.
Transformation assays
A subclonal NIH 3T3 cell line, which was selected to express a very low level of EGFR previously (Gotoh et al., 1992 (Gotoh et al., , 1994 , was co-transfected with the expression vector for EGFR carrying hygromycin-resistance gene and empty vector, or the expression vector for SNT-2-FLAG carrying neomycineresistance gene by LipofectAMINEt 2000. The transfected cells were grown in DMEM containing 5% NBCS in the presence or absence of EGF (10 ng/ml), and were selected with hygromycin (200 mg/ml, for EGFR) and G418 (200 mg/ml) together. Media were changed every 2 days. After 3 weeks, the numbers of hygromycin-G418 resistant colonies and transformed colonies were counted as described (Gotoh et al., 1992) .
Ras activity assays
We used Ras activation assay kit (Upstate cell signaling solutions) following the protocol from the company. Briefly, stable transfectants of Saos-2 cells were stimulated with EGF after 24 h of starvation and the lysates were incubated with GST-RBD agarose for 30 min at 41C. The total lysates and the protein conjugated to the agarose were analysed by immunoblotting with anti-H-Ras.
In vitro binding assays Escherichia coil BL21 carrying GST or GST-ERK2 plasmids was grown in Luria-Bertani (LB) medium containing 50 mg/ml ampicillin and incubated with 0.5 mM isopropyl-thiogalactopyranoside (IPTG) at 281C for 3 h. The bacteria carrying induced GST-fusion proteins were lysed as described (Huang et al., 2004) and the cell lysates were incubated at 41C for 1 h with glutathione-Sepharose beads GE healthcare life sciences (Amersham Biosciences, Piscataway, NJ, USA). HEK 293 cells transfected with full length or truncation mutants of SNT-2-FLAG were lysed with the binding buffer (20 mM Hepes, 150 mM NaCl, 1 mM EDTA, 1% Triton X-100, 5% glycerol, 10 mM pyrophosphate, 1 mM Na 3 VO 4 , 1 mM phenylmethylsulfonylfluoride (PMSF), 5 mg/ml aprotinin, and 5 mg/ml leupeptin (pH 7.5)) at 41C for 10 min. After centrifugation, the cell lysates were mixed with glutathione-Sepharose beads immobilized with GST fusion proteins at 41C for 2 h. Proteins were eluted with 1 Â sample buffer, subjected to sodium dodecyl sulfatepolyacrylamide gel electrophoresis (SDS-PAGE), and immunoblotted with anti-GST, anti-ERK2 or anti-FLAG M2 antibody.
Co-immunoprecipitation assays
Saos-2 cells or HEK 293 cells were starved for 24 h before EGF treatment. Cells were lysed in the binding buffer and the cell lysates were incubated with anti-EGFR polyclonal antibodies at 41C for 1 h and with protein A-Sepharose (Amersham Biosciences) for additional 1 h. The immunoprecipitates were immunoblotted with anti-FLAG M2 monoclonal and anti-EGFR antibodies.
Northern blotting RNA from mouse brain and NIH3T3 cells were prepared using a standard method (Gotoh et al., 2005) . Probes for mouse Frs2a and Frs2b were previously described (Gotoh et al., 2004b) .
Cell growth assays NIH3T3 cells expressing EGFR with or without SNT-2 or D237-252 were seeded at 2 Â 10 4 cells/35 mm dish in DMEM containing 1% NBCS. Subsequently, the media were changed to 1% NBCS with or without EGF (20 ng/ml). The media were further changed every 2 days and the cell number was counted daily from the second day of EGF treatment.
Soft agar colony formation assays NIH3T3 cells expressing EGFR with or without SNT-2 or D237-252 were seeded at 5 Â 10 4 cells/35 mm dish in 2 ml of DMEM containing 10% NBCS and 0.36% agarose with or without EGF (20 ng/ml) on the top of existing 0.72% bottom agarose in triplicate. After 3 weeks, cell colonies >0.1 mm in diameter were counted.
